INmune Bio financials
$1.96−2.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $50.0K | $0.00 | $0.00 | $0.00 | $14.0K | $28.0K | $43.0K |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $50.0K | $0.00 | $0.00 | $0.00 | $14.0K | $28.0K | $43.0K |
| Gross margin | — | — | — | — | — | 100.0% | — | — | — | 100.0% | 100.0% | 100.0% |
| Operating income | -$1.5M | -$5.8M | -$5.5M | -$7.4M | -$24.6M | -$9.9M | -$9.5M | -$12.3M | -$9.9M | -$11.0M | -$8.4M | -$8.5M |
| Net income | -$1.3M | -$5.4M | -$5.3M | -$6.5M | -$24.5M | -$9.7M | -$9.2M | -$12.1M | -$9.7M | -$11.0M | -$8.4M | -$8.6M |
| Net margin | — | — | — | — | — | −19478.0% | — | — | — | −78750.0% | −30028.6% | −19914.0% |
| Diluted EPS | $-0.05 | $-0.20 | $-0.20 | $-0.24 | $-1.05 | $-0.43 | $-0.41 | $-0.60 | $-0.50 | $-0.61 | $-0.47 | $-0.48 |
| EBITDA | -$1.4M | -$5.8M | -$5.4M | -$7.4M | -$8.1M | -$9.9M | -$9.5M | -$12.3M | -$9.9M | -$11.0M | -$8.4M | -$8.5M |
| Operating cash flow | -$3.2M | -$3.4M | -$2.9M | -$5.4M | -$7.4M | -$6.8M | -$11.0M | -$7.0M | -$7.9M | -$7.5M | -$3.4M | -$4.3M |
| Free cash flow | -$3.6M | -$3.4M | -$3.1M | -$5.6M | -$8.1M | -$6.8M | -$11.0M | -$7.0M | -$7.9M | -$7.5M | -$3.4M | -$4.3M |
| Diluted shares | 26.7M | 26.6M | 26.7M | 26.6M | 23.3M | 22.5M | 22.3M | 20.2M | 19.3M | 18.0M | 18.0M | 18.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $18.4M | $21.4M | $24.8M | $27.7M | $33.4M | $19.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $26.8M | $25.8M | $32.4M | $33.4M | $37.7M | $37.8M |
| Total liabilities | $6.5M | $6.2M | $8.8M | $8.0M | $8.8M | $8.1M |
| Shareholders' equity | $20.4M | $19.6M | $23.5M | $25.4M | $28.9M | $29.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology